SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)
Open Access
- 5 February 2022
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 24 (4) , 635-645
Abstract
Thymic epithelial tumours (TET) represent a heterogeneous group of rare malignancies that include thymomas and thymic carcinoma. Treatment of TET is based on the resectability of the tumour. If this is considered achievable upfront, surgical resection is the cornerstone of treatment. Platinum-based chemotherapy is the standard regimen for advanced TET. Due to the rarity of this disease, treatment decisions should be discussed in specific multidisciplinary tumour boards, and there are few prospective clinical studies with new strategies. However, several pathways involved in TET have been explored as potential targets for new therapies in previously treated patients, such as multi-tyrosine kinase inhibitors with antiangiogenic properties and immune checkpoint inhibitors (ICI). One third of patient with thymoma present an autoimmune disorders, increasing the risk of immune-related adverse events and autoimmune flares under ICIs. In these guidelines, we summarize the current evidence for the therapeutic approach in patients with TET and define levels of evidence for these decisions.Keywords
This publication has 44 references indexed in Scilit:
- Thymic Carcinoma: A Cohort Study of Patients from the European Society of Thoracic Surgeons DatabaseJournal of Thoracic Oncology, 2014
- Thymic epithelial tumours: from basic principles to individualised treatment strategiesEuropean Respiratory Review, 2013
- Thymoma: A Population-Based Study of the Management and Outcomes for the Province of British ColumbiaJournal of Thoracic Oncology, 2013
- The Masaoka-Koga Stage Classification for Thymic Malignancies: Clarification and Definition of TermsJournal of Thoracic Oncology, 2011
- Aire and T cell developmentCurrent Opinion in Immunology, 2011
- Evaluation and Treatment of Stage I and II ThymomaJournal of Thoracic Oncology, 2010
- The Role of Surgery in the Management of Thymoma: A Systematic ReviewThe Annals of Thoracic Surgery, 2008
- Pleuropneumonectomy for the Treatment of Masaoka Stage IVA ThymomaThe Annals of Thoracic Surgery, 2006
- Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant RecipientsClinical Infectious Diseases, 2001
- Retreatment of Recurrent Invasive Thymoma with Platinum, Doxorubicin, and CyclophosphamideChest, 1996